PURPOSE To evaluate the antitumor activity of combination cisplatin (CDDP) and alpha-
interferon (alpha-IFN) in advanced, measurable metastatic melanoma. PATIENTS AND …

The purpose of this trial was to determine the toxicity and antineoplastic activity of cisplatin,
carboplatin, tamoxifen, and interferon-α (IFN-α) in patients with advanced melanoma. Eleven …

Based on encouraging reports of improved response rates with the use of dacarbazine
(DTIC) in combination with recombinant interferon alpha-2a (rIFN-α-2a) in patients with …

Systemic chemotherapy for the treatment of metastatic melanoma remains disappointing.
Nor new single agent has demonstrated promising results. The combination of cisplatin …

PURPOSE Some phase II studies have suggested that the combination of interferons (IFNs)
with dacarbazine (DTIC) in the treatment of malignant melanoma (MM) increases the …

BACKGROUND Metastatic melanoma is a disease associated with a poor prognosis, and
dacarbazine is still the reference agent. The authors conducted a randomized trial to test the …

The primary objective of this study was to determine the safety, toxicity, and maximum
tolerated dose of nanoparticle albumin-bound (nab)-paclitaxel as part of biochemotherapy …

A prospectively randomized trial was undertaken to compare dacarbazine (DTIC) alone with
DTIC plus interferon in patients with metastatic malignant melanoma. Of the 73 patients who …

The role of medical treatment in advanced or metastatic malignant melanoma is still
controversial, and there is no standard systemic therapy. Dacarbazine has been the most …

Biochemotherapy, which uses recombinant interferon alpha (rIFN-alpha) and recombinant
interleukin-2 (rIL-2) in combination with chemotherapy is a promising therapy for metastatic …